Watch CYCN. Know when insiders buy.
One email the day a filing lands. Free.
CYCN
Cyclerion Therapeutics, Inc.
23.94
−5.81 −19.53%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
15
FLAG · shorts 15
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $112.1MP/E —DIV YIELD —FCF YIELD —REV TTM $1.9M −12.6%NET INCOME −$6.7MNET CASH —52W 7.56 – 44.66SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$1.8M | −$1.8M | — | -0.41 | −$1.4M | $0 | −$1.4M | Aug 4 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$3.2M | −$3.2M | — | -0.76 | −$1.2M | $66K | −$1.2M | Aug 4 |
| Q4 2025 · Dec 31derived | $1M | −43.2% | — | −$838K | −$799K | −250.8% | -0.19 | −$1.6M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | $875K | +351.0% | — | −$1M | −$976K | — | -0.30 | −$264K | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $93K | — | — | −$1.7M | −$324K | — | -0.11 | −$503K | $0 | −$503K | Aug 4 |
| Q1 2025 · Mar 31 | $81K | — | — | −$1.5M | −$1.4M | — | -0.56 | −$968K | $0 | −$968K | Aug 4 |
| Q4 2024 · Dec 31derived | $1.8M | — | — | $502K | $530K | — | 0.22 | $360K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | $194K | — | — | −$1.1M | −$723K | −109.6% | -0.29 | −$1.7M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$1.4M | −$1.3M | — | -0.53 | −$1.1M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | $0 | — | — | −$1.6M | −$1.5M | — | -0.62 | −$1.9M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$1.8M | −$1.7M | — | -0.70 | −$1.5M | — | — | Nov 12 |
| Q3 2023 · Sep 30 | $0 | — | — | −$6M | $7.6M | — | 2.72 | −$6.9M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.1M | — | −$5M | −$3.5M | -170.1% | -1.11 | −$3.3M | — | — | — | — |
| FY2024 · to Dec 31 | $2M | — | −$3.6M | −$3.1M | -152.8% | -1.21 | −$4.3M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$13M | −$5.3M | — | -2.25 | −$21.2M | — | — | — | — |
| FY2022 · to Dec 31 | $297K | — | −$18.5M | −$44.1M | -14841.1% | -20.28 | −$40.6M | $0 | −$40.6M | — | — |
| FY2021 · to Dec 31 | $3.9M | — | −$55.2M | −$51.6M | -1310.2% | -1.32 | −$36.5M | $7K | −$36.5M | — | — |
| FY2020 · to Dec 31 | $2.3M | — | −$81.3M | −$77.8M | -3388.6% | -2.56 | −$72.5M | $1.5M | −$74M | — | — |
Every number comes from Cyclerion Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.